{"blog": [], "keywords": [{"value": "Medical Devices", "name": "subject", "rank": "1", "is_major": "N"}, {"value": "Epinephrine (Drug)", "name": "subject", "rank": "2", "is_major": "Y"}, {"value": "Prices (Fares, Fees and Rates)", "name": "subject", "rank": "3", "is_major": "N"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "4", "is_major": "Y"}, {"value": "Trademarks and Trade Names", "name": "subject", "rank": "5", "is_major": "N"}, {"value": "Mylan Inc", "name": "organizations", "rank": "6", "is_major": "Y"}, {"value": "Bresch, Heather", "name": "persons", "rank": "7", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/09/04/opinion/sunday/the-lesson-of-epipens-why-drug-prices-spike-again-and-again.html", "document_type": "article", "byline": {"person": [{"lastname": "ROSENTHAL", "firstname": "Elisabeth", "role": "reported", "organization": "", "rank": 1}], "original": "By ELISABETH ROSENTHAL"}, "type_of_material": "Op-Ed", "multimedia": [{"url": "images/2016/09/04/opinion/sunday/04rosenthal/04rosenthal-thumbWide.jpg", "legacy": {"wide": "images/2016/09/04/opinion/sunday/04rosenthal/04rosenthal-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/09/04/opinion/sunday/04rosenthal/04rosenthal-articleLarge.jpg", "legacy": {"xlarge": "images/2016/09/04/opinion/sunday/04rosenthal/04rosenthal-articleLarge.jpg", "xlargeheight": "440", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 440}, {"url": "images/2016/09/04/opinion/sunday/04rosenthal/04rosenthal-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/09/04/opinion/sunday/04rosenthal/04rosenthal-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Opinion", "word_count": "1217", "source": "The New York Times", "subsection_name": "Sunday Review", "lead_paragraph": "Government has no real tools to curb extortionate prices.", "pub_date": "2016-09-04T04:00:00+0000", "news_desk": "OpEd", "headline": {"kicker": "Opinion", "print_headline": "Old Drug, Pricey New Package", "main": "The Lesson of EpiPens: Why Drug Prices Spike, Again and Again", "content_kicker": "Opinion"}, "print_page": "2", "snippet": "Government has no real tools to curb extortionate prices....", "_id": "57c9b2b395d0e021d79841ab", "slideshow_credits": null, "abstract": "Op-Ed article by Elisabeth Rosenthal points to controversy surrounding Mylan's increase of prices on EpiPen auto-injectors as example of how federal government has no tools with which to regulate pharmaceutical industry's pricing practices; result is often prohibitive consumer costs for life-saving drugs."}